782
Participants
Start Date
May 30, 2019
Primary Completion Date
January 30, 2025
Study Completion Date
January 30, 2025
Evolocumab
REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
Placebo
Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
Jacksonville Center for Clinical Research, Jacksonville
University Hospital Cleveland Medical Center, Cleveland
Minneapolis Heart Institute Foundation, Minneapolis
San Francisco VA Medical Center, San Francisco
Maine Medical Center, Portland
Royal Adelaide Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Monash University, Melbourne
Fiona Stanley Hospital, Murdoch
New Brunswick Heart Centre, Saint John's
Hamilton Health Sciences, Hamilton
One Heart Care, Mississauga
North York Diagnostic and Cardiology Centre, North York
Sunnybrook Health Sciences Center, North York
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec
Foothills Medical Centre, Calgary
Medical Centre Hungarian Defence Forces, Budapest
Semmelweis University Heart and Vascular Centre, Budapest
Zala Megyei Szent Rafael Korhaz, Zalaegerszeg
University of Alberta, Edmonton
Kingston Health Sciences Centre, Kingston
St. Michael's Hospital, Toronto
Collaborators (1)
Applied Health Research Centre
OTHER
Unity Health Toronto
OTHER